Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

151.94
-2.3850-1.55%
Volume:25.93K
Turnover:3.95M
Market Cap:9.83B
PE:147.51
High:158.08
Open:154.32
Low:150.00
Close:154.32
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.41
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.68
PE(LYR):-74.11

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies

Reuters
·
Mar 19

Protagonist Therapeutics Inc : JP Morgan Raises Target Price to $106 From $95

THOMSON REUTERS
·
Mar 18

BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist

Reuters
·
Mar 18

BUZZ-Protagonist climbs after FDA approves oral psoriasis drug

Reuters
·
Mar 18

Shares of Protagonist Therapeutics Rise 4% Premarket After U.S. FDA Approves Co's, Johnson & Johnson’s Oral Psoriasis Drug

THOMSON REUTERS
·
Mar 18

Protagonist Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Mar 03

Protagonist Therapeutics price target raised to $100 from $86 at Wedbush

TIPRANKS
·
Mar 02

Wedbush Remains a Buy on Protagonist Therapeutics (PTGX)

TIPRANKS
·
Mar 02

Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating

MT Newswires Live
·
Mar 02

Takeda, Protagonist announce FDA acceptance of rusfertide new drug application

TIPRANKS
·
Mar 02

FDA accepts Takeda NDA for rusfertide and grants Priority Review

Reuters
·
Mar 02

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

THOMSON REUTERS
·
Mar 02

Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA Filing And Takeda Deal Shift - What's Changed

Simply Wall St.
·
Mar 01

Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan

TIPRANKS
·
Feb 27

Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines

TIPRANKS
·
Feb 27

Protagonist Therapeutics Is Maintained at Market Outperform by Citizens

Dow Jones
·
Feb 26

U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite

Reuters
·
Feb 26

Protagonist Therapeutics Inc : TD Cowen Raises Target Price to $100 From $90

THOMSON REUTERS
·
Feb 26

Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target

TIPRANKS
·
Feb 26

Protagonist Therapeutics Q4 EPS $(0.69) Misses $(0.24) Estimate, Sales $7.437M Miss $8.926M Estimate

Benzinga Earnings
·
Feb 26